Miranda Durkie1, Jiehan Chong2, Manoj K Valluru2, Peter C Harris3, Albert C M Ong4. 1. Sheffield Diagnostics Genetic Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK. 2. Kidney Genetics Group, Academic Nephrology Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical School, Sheffield, UK. 3. Division of Nephrology and Hypertension, Mayo Clinic and Foundation, Rochester, MN, USA. 4. Kidney Genetics Group, Academic Nephrology Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical School, Sheffield, UK. a.ong@sheffield.ac.uk.
Abstract
PURPOSE: To investigate the prevalence of biallelic PKD1 and PKD2 variants underlying very early onset (VEO) polycystic kidney disease (PKD) in a large international pediatric cohort referred for clinical indications over a 10-year period (2010-2020). METHODS: All samples were tested by Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA) of PKD1 and PKD2 genes and/or a next-generation sequencing panel of 15 additional cystic genes including PKHD1 and HNF1B. Two patients underwent exome or genome sequencing. RESULTS: Likely causative PKD1 or PKD2 variants were detected in 30 infants with PKD-VEO, 16 of whom presented in utero. Twenty-one of 30 (70%) had two variants with biallelic in trans inheritance confirmed in 16/21, 1 infant had biallelic PKD2 variants, and 2 infants had digenic PKD1/PKD2 variants. There was no known family history of ADPKD in 13 families (43%) and a de novo pathogenic variant was confirmed in 6 families (23%). CONCLUSION: We report a high prevalence of hypomorphic PKD1 variants and likely biallelic disease in infants presenting with PKD-VEO with major implications for reproductive counseling. The diagnostic interpretation and reporting of these variants however remains challenging using current American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) and Association of Clinical Genetic Science (ACGS) variant classification guidelines in PKD-VEO and other diseases affected by similar variants with incomplete penetrance.
PURPOSE: To investigate the prevalence of biallelic PKD1 and PKD2 variants underlying very early onset (VEO) polycystic kidney disease (PKD) in a large international pediatric cohort referred for clinical indications over a 10-year period (2010-2020). METHODS: All samples were tested by Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA) of PKD1 and PKD2 genes and/or a next-generation sequencing panel of 15 additional cystic genes including PKHD1 and HNF1B. Two patients underwent exome or genome sequencing. RESULTS: Likely causative PKD1 or PKD2 variants were detected in 30 infants with PKD-VEO, 16 of whom presented in utero. Twenty-one of 30 (70%) had two variants with biallelic in trans inheritance confirmed in 16/21, 1 infant had biallelic PKD2 variants, and 2 infants had digenic PKD1/PKD2 variants. There was no known family history of ADPKD in 13 families (43%) and a de novo pathogenic variant was confirmed in 6 families (23%). CONCLUSION: We report a high prevalence of hypomorphic PKD1 variants and likely biallelic disease in infants presenting with PKD-VEO with major implications for reproductive counseling. The diagnostic interpretation and reporting of these variants however remains challenging using current American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) and Association of Clinical Genetic Science (ACGS) variant classification guidelines in PKD-VEO and other diseases affected by similar variants with incomplete penetrance.
Authors: Zhengmao Zhang; Hanwen Bai; Jon Blumenfeld; Andrew B Ramnauth; Irina Barash; Martin Prince; Adrian Y Tan; Alber Michaeel; Genyan Liu; Ines Chicos; Lior Rennert; Stavros Giannakopoulos; Karen Larbi; Stuart Hughes; Steven P Salvatore; Brian D Robinson; Sandip Kapur; Hanna Rennert Journal: J Am Soc Nephrol Date: 2021-10-29 Impact factor: 10.121
Authors: Sarah R Senum; Ying Sabrina M Li; Katherine A Benson; Giancarlo Joli; Eric Olinger; Sravanthi Lavu; Charles D Madsen; Adriana V Gregory; Ruxandra Neatu; Timothy L Kline; Marie-Pierre Audrézet; Patricia Outeda; Cherie B Nau; Esther Meijer; Hamad Ali; Theodore I Steinman; Michal Mrug; Paul J Phelan; Terry J Watnick; Dorien J M Peters; Albert C M Ong; Peter J Conlon; Ronald D Perrone; Emilie Cornec-Le Gall; Marie C Hogan; Vicente E Torres; John A Sayer; Peter C Harris Journal: Am J Hum Genet Date: 2021-12-09 Impact factor: 11.043
Authors: Jennifer Arroyo; Diana Escobar-Zarate; Harrison H Wells; Megan M Constans; Ka Thao; Jessica M Smith; Cynthia J Sieben; Madeline R Martell; Timothy L Kline; Maria V Irazabal; Vicente E Torres; Katharina Hopp; Peter C Harris Journal: Kidney Int Date: 2021-03-09 Impact factor: 18.998
Authors: Gianpiero L Cavalleri; Peter Conlon; Katherine A Benson; Susan L Murray; Sarah R Senum; Elhussein Elhassan; Eoin T Conlon; Claire Kennedy; Shane Conlon; Edmund Gilbert; Dervla Connaughton; Paul O'Hara; Sarah Khamis; Sarah Cormican; Lawrence C Brody; Anne M Molloy; Sally Ann Lynch; Liam Casserly; Matthew D Griffin; Robert Carton; Kevin Yachnin; Peter C Harris Journal: Eur J Hum Genet Date: 2021-01-16 Impact factor: 5.351
Authors: Filippo Pinto E Vairo; Carri Prochnow; Jennifer L Kemppainen; Emily C Lisi; Joan M Steyermark; Teresa M Kruisselbrink; Pavel N Pichurin; Rhadika Dhamija; Megan M Hager; Sam Albadri; Lynn D Cornell; Konstantinos N Lazaridis; Eric W Klee; Sarah R Senum; Mireille El Ters; Hatem Amer; Linnea M Baudhuin; Ann M Moyer; Mira T Keddis; Ladan Zand; David J Sas; Stephen B Erickson; Fernando C Fervenza; John C Lieske; Peter C Harris; Marie C Hogan Journal: Kidney Med Date: 2021-06-29
Authors: Alanna Strong; Laurie Simone; Anthony Krentz; Courtney Vaccaro; Deborah Watson; Hayley Ron; Jennifer M Kalish; Helio F Pedro; Elaine H Zackai; Hakon Hakonarson Journal: Am J Med Genet A Date: 2021-06-15 Impact factor: 2.802